spacer
home > > autumn 2008 > commitment issues
PUBLICATIONS


Commitment Issues

As with all regulations, some are easier to follow than others. There are always going to be scenarios ‘at the margins’ where any regulation will struggle to define the correct procedure or process for dealing with a specific issue, or may appear to be in conflict with some other aspect of best practice.

This has been amply illustrated within the laboratory sector in recent times, with the delayed implementation of General Chapter <467> Residual Solvents of the United States Pharmacopoeia – National Formulary (USP-NF). This proposed revision to the USP-NF had first been scheduled for introduction on 1st January 2007, only for implementation to be delayed until 1st July 2007, and then further delayed with an implementation date of 1st July 2008.

BACKGROUND TO CHAPTER <467>

The essential rationale behind USP <467> is an attempt to harmonise test standards for residual solvents for medicines sold in the US in accordance with a model already adopted by the European Pharmacopeia. It aims to prescribe standard test methods for three classes of solvent. These are:

  • Class 1 solvents, a defined list of chemicals that are known or suspected to be human carcinogens
  • Class 2 solvents, a defined list known to be animal carcinogens or to exhibit other toxicity
  • Class 3 solvents, a defined list of chemicals having low toxic potential

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Philip Payne is Business Development Manager for RSSL Pharma. He joined from Italian API producer, Steroid, where he was General Manager with responsibility for sales, procurement, production and analysis. Fluent in Italian, French and English, and with broad experience of research and production, Philip now assists RSSL Pharma in promoting its analytical and training services more widely across Europe, in addition to the UK and Ireland.
spacer
Philip Payne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Autoinjector testing made safe efficient and flexible

ZwickRoell

The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement